Casey Ager

Assistant Professor at Mayo Clinic | Cancer Immunology

[Casey Ager @caseyager]

Today the Ager Lab at @MayoClinic officially opened its doors! So thrilled to start this adventure, and thankful to friends and mentors that helped me get here.

I’m recruiting at all levels, so please RT to spread the word! More info at our website:

https://t.co/VfOQvkonAl

[Mayo Clinic Urology @MayoUrology]

Congratulations to Dr. Casey Ager and his lab for their first R01 from the NCI! The 5-year grant is to study the role of TRPS1 in antitumor activity. This will hopefully lead to the discovery of a new therapeutic target for GU cancers and potentially other cancer types.

[Cell Reports Medicine @CellRepMed]

Online now: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial https://t.co/DjZccki0jE

[Casey Ager @caseyager]

Great work @ZakhariaYousef!

[Mayo Clinic @MayoClinic]

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year. At Mayo Clinic, Yousef Zakharia, M.D., a medical oncologist and chair of the Genitourinary Disease Group at the Mayo Clinic Comprehensive Cancer Center, leads clinical research aimed at improving outcomes for patients with kidney, bladder and prostate cancers.

Learn more: https://t.co/JK6Dx5ZbOd

[Casey Ager @caseyager]

Thanks @MayoClinic for the highlight. We’re thrilled to see this out!

For any interested in reading deeper, the study in full can be accessed here: https://t.co/rnx2FKmSVD
#ASCOGU2026

[Mayo Clinic @MayoClinic]

A Mayo Clinic-led study in Cell Reports Medicine shows a new immunotherapy + hormone therapy combo could overcome a major barrier in early-stage prostate cancer treatment, offering hope for patients at high risk.

Learn more about this groundbreaking study and its potential impact: https://t.co/Awhrc2qAQG | @caseyager

[Casey Ager @caseyager]

And here’s the link to our prior tweetorial on the pre-print for more detail, with proper shoutouts to our amazing collaborative team:

[Casey Ager @caseyager]

New pre-print out! 🚨

Targeted Treg depletion has been a long sought-after goal in cancer, with few if any clinical successes to date. Next-gen CTLA-4 drugs have been engineered for this purpose, but do they work? Read on to find out:
🧵 (1/17)

https://t.co/hFTn2wQcF4

[Casey Ager @caseyager]

🚨Excited to share our latest study on immunotherapy for prostate cancer, out today at @CellRepMed!

We hope this paves the way for further translation of Fc-enhanced CTLA-4 antibodies by showing evidence of tumor Treg depletion in patients.

https://t.co/rnx2FKnqLb

[Casey Ager @caseyager]

Fitting day to have our first Treg-focused paper from the lab published! Congrats to superstar postdoc Nilika Bhattacharya for her hard work perfecting this 38-marker spectral flow panel to dissect human Treg heterogeneity
https://t.co/FcjoYCjQKY
#NobelPrize #Tregs @MayoClinic

[Fabrice Lucien, PhD @flscientist]

Delaying the use of ADT in oligorecurrent prostate cancer treated with SBRT but for who? Integration of imaging- and blood-based tumor burden estimation to select the right patients.
@MayoUrology @MayoRadOnc @MayoCancerCare

https://t.co/phstygBnbv

[Casey Ager @caseyager]

Landmark day in the lab as flow guru and awesome postdoc @CollinJugler runs the first 51-color flow cytometry experiment in lab history! Breaking the 50-marker mark in style with help from our friends at @CytekBio @BDBiosciences #CYTO2025

[Fabrice Lucien, PhD @flscientist]

Excited to share our recent multi-center study showing PSMA+EVs are prognostic and predictive in oligometastatic prostate cancer treated with SBRT. Validation studies are ongoing. A future for EV-guided therapy! @MayoUrology @MayoRadOnc

https://t.co/yWAy1bJuuE

[Casey Ager @caseyager]

@SGoswamiMDPhD @DeblinaRC @RaiPratishtha @MDAndersonNews Congrats Sangeeta!

[Casey Ager @caseyager]

@ScienceCourtney @MayoClinic @JuglerCollin Thanks Courtney! Hope you’re well!!

[Casey Ager @caseyager]

Thankful and proud of my awesome team who worked together tirelessly over the last week getting the Ager Lab up and running in our shiny new lab space at @MayoClinic’s new Integrated Education and Research Building (IERB) on Mayo’s Phoenix campus!

[Casey Ager @caseyager]

@Parminder1699 @MayoClinic @JuglerCollin Absolutely! Glad to be neighbors and looking forward to teaming up Parminder

[Casey Ager @caseyager]

We’d love to hear your feedback! For those interested, my lab at Mayo AZ (@MayoClinic @MayoCancerCare @MayoUrology) is eagerly digging into these mechanisms to develop new and better immunotherapy approaches for prostate cancer. Please join us…. or fund us!! (17/17)

[Casey Ager @caseyager]

Prostate tumors are notoriously poorly immune infiltrated, so access to surgical tissue afforded the rare opportunity for orthogonal immune profiling by CyTOF, scRNAseq and spatial. As in our past work, @califano_lab’s PISCES pipeline brought the scRNAseq data to life.
(6/17)

[Casey Ager @caseyager]

Another huge thank you to the many additional contributors not called out here that put so much effort into this study. It was as a huge team effort. And of course, thank you most of all to patients and their families for participating in this study! (16/17)